Key result
Avatrombopag sustains platelet response for ~12 weeks in ITP and cuts transfusions in chronic liver disease.
Why the study?
Does avatrombopag improve platelet response and reduce the need for platelet transfusions or rescue procedures in adult patients with chronic ITP or CLD?
Population
Adult patients with chronic ITP or chronic liver disease scheduled for an invasive procedure
Comparison
Avatrombopag vs placebo
Design
Narrative review of phase III clinical trials
Authors
Loading...
Supports avatrombopag as oral option for refractory ITP and periprocedural CLD thrombocytopenia; extends TPO-RA class evidence to second-generation agents.
Does avatrombopag improve platelet response and reduce the need for platelet transfusions or rescue procedures in adult patients with chronic ITP or CLD?
Absolute Event Rate: 12% vs 0.1%
p-value: p=<0.0001
Avatrombopag is an effective oral treatment for increasing platelet counts in chronic ITP and preventing bleeding events in CLD patients undergoing invasive procedures.
Anthony Markham (2021) conducted a review in Thrombocytopenia (chronic ITP and CLD). Avatrombopag vs. Placebo was evaluated on Cumulative mean number of weeks of platelet response without needing rescue therapy (ITP trial) (p=<0.0001). Avatrombopag significantly increased the cumulative weeks of platelet response in chronic ITP (12 vs 0.1 weeks) and reduced the need for platelet transfusions in patients with chronic liver disease compared to placebo.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: